Prolactin-producing pituitary tumours are among the most common types of pituitary growths, and while they can cause significant health challenges, the good news is that most cases respond well to treatment with medication. Understanding the available treatment options and what research is currently exploring can help patients and families make informed decisions about care.

Understanding How Treatment Helps Manage Prolactinomas

When someone is diagnosed with a prolactin-producing pituitary tumour, also called a prolactinoma, the main goals of treatment focus on bringing hormone levels back to normal, reducing the size of the tumour if necessary, and relieving symptoms that affect daily life. These symptoms can range from irregular menstrual periods and difficulty getting pregnant in women, to erectile problems and reduced interest in sex in men. Both sexes may experience headaches, vision changes, and infertility^[1][2].

The treatment approach depends heavily on several factors. The size of the tumour matters significantly—doctors classify prolactinomas as microprolactinomas when they are smaller than one centimeter, and macroprolactinomas when they exceed that size. Women are more likely to have smaller tumours, often because symptoms appear earlier and prompt medical attention. Men, on the other hand, tend to have larger tumours at diagnosis because their symptoms may be less obvious initially^[2][3].

Treatment decisions also take into account whether the tumour is causing symptoms, whether the patient wishes to become pregnant, and whether the growth is pressing on nearby structures like the optic nerves that control vision. Some people with very small prolactinomas that cause no symptoms may not need immediate treatment at all—instead, doctors monitor them carefully over time^[9].

Modern medicine offers several established treatment methods approved by medical societies worldwide, and researchers continue to investigate new therapies through clinical trials. The landscape of treatment has evolved considerably, with medical therapy now serving as the first-line approach for most patients, while surgery and radiation remain important options for specific situations^[6][12].

Standard Medical Treatment with Dopamine Agonists

For the vast majority of people with prolactinomas, medication provides the most effective treatment. Drugs known as dopamine agonists form the cornerstone of standard therapy. These medicines work by mimicking the natural brain chemical dopamine, which normally keeps prolactin production in check. When a prolactinoma develops, this natural regulation goes awry, and dopamine agonists help restore balance^[9][11].

The most commonly prescribed dopamine agonist is cabergoline, marketed under the brand name Dostinex. This medication has several advantages that make it particularly popular among doctors and patients alike. It only needs to be taken once or twice per week because it stays active in the body for a long time. The typical dose ranges from half a milligram to one milligram weekly, though some patients require higher amounts. Most people tolerate cabergoline very well, and it successfully brings prolactin levels down to normal in about 80 to 90 percent of cases^[11][6].

Another medication, bromocriptine, sold as Parlodel, has been used for many years and remains an effective option. Unlike cabergoline, bromocriptine requires dosing two or three times daily, with a typical dose of 2.5 milligrams per administration. While effective, some patients find the more frequent dosing schedule less convenient^[11].

A third dopamine agonist called quinagolide, known by the brand name Norprolac, is taken once daily. Doctors usually start patients on a low dose and gradually increase it to 75 micrograms to minimize side effects. This medication is less commonly used than the other two but provides another valuable option for patients who may not respond well to or tolerate the other medications^[11].

The effects of dopamine agonist medication often become apparent quite quickly. Prolactin levels typically fall to normal within just a few weeks of starting treatment. For women, this means menstrual cycles usually return to normal, interest in sexual activity is regained, and fertility is restored in most cases. Men often experience rising testosterone levels, which improves sex drive and potency. Beyond controlling hormone levels, these medications also shrink nearly all prolactinomas. For patients whose tumours press on the optic nerves causing vision problems, improvement in eyesight often occurs as the tumour shrinks away from these delicate structures^[11][9].

The duration of treatment varies from person to person. Some individuals need to take dopamine agonists for life to keep their prolactin levels under control and prevent tumour regrowth. Others can stop taking the medication after two to three years, especially if their tumour was small when discovered or has disappeared completely on follow-up brain scans. However, there is always a risk that the tumour may grow back and start producing prolactin again after stopping medication, particularly if it was large initially. Regular monitoring with blood tests and brain imaging helps doctors and patients make informed decisions about continuing or stopping treatment^[8][11].

Understanding Potential Side Effects

While dopamine agonists are generally safe and well-tolerated, they can cause side effects in some people. The most common complaints include dizziness when standing up suddenly, nausea, headaches, and constipation. These side effects are usually mild and often diminish as the body becomes accustomed to the medication. Increasing dietary fiber can help with constipation. Other possible side effects include tiredness, abdominal discomfort, breast tenderness, and nasal congestion^[11].

More concerning but rare complications involve psychological changes. Some patients taking dopamine agonists, particularly at higher doses or when doses are increased, may develop impulse control disorders. These can manifest as pathological gambling, hypersexuality, compulsive shopping, or other unusual behaviours. Because these behaviours are so unusual, people often don’t connect them to their medication. Patients and their family members should be aware of this possibility and seek help from their doctor immediately if they notice such changes. Being alert to these potential effects allows for early intervention and adjustment of treatment^[11].

High doses of cabergoline have also been associated with heart valve changes in some patients, particularly those taking much higher doses than typically used for prolactinomas. Regular monitoring helps detect any such issues early. If side effects become severe or unbearable despite attempts to manage them, switching to a different dopamine agonist or considering alternative treatments like surgery may be necessary^[6].

Surgical Treatment Options

While medication successfully treats most prolactinomas, surgery becomes necessary in certain situations. Surgery is typically recommended when medication fails to control prolactin levels or shrink the tumour adequately, when patients cannot tolerate the medications due to severe side effects, or when symptoms are severe and require rapid intervention—such as sudden vision loss or signs of pituitary apoplexy, a rare emergency where the tumour suddenly bleeds^[9][11].

The most common surgical approach is called transsphenoidal surgery. This technique is remarkable because it allows neurosurgeons to reach the pituitary gland without making any external incisions on the face or skull. Instead, surgeons access the pituitary through the nose and sinuses using specialized instruments. Many centers now use endoscopic transsphenoidal surgery, which employs a thin, flexible tube with a camera to provide high-definition views of the surgical area. This minimally invasive approach typically results in less pain, shorter hospital stays, and faster recovery compared to older surgical methods^[14][5].

For very large tumours that have grown beyond the normal boundaries of the pituitary region, a craniotomy may be necessary. This involves making an opening in the skull to directly access the tumour. However, this approach is less common for prolactinomas specifically^[5].

Surgery for prolactinomas is generally more successful when performed by experienced pituitary surgeons at high-volume centers that treat many such cases each year. Success rates depend on tumour size and location. Microprolactinomas can often be completely removed, potentially curing the condition. Larger macroprolactinomas are more challenging to remove entirely because they may grow into surrounding structures. Some patients may still need medication after surgery if the tumour cannot be completely removed or if prolactin levels remain elevated^[11][14].

Some doctors recommend a course of dopamine agonist medication before surgery to shrink the tumour and make it easier to remove. This preoperative medical therapy can potentially improve surgical outcomes, though practices vary among medical centers^[6].

Radiation Therapy for Resistant Cases

Radiation therapy is rarely needed for prolactinomas but remains an important option for specific circumstances. It’s typically reserved for tumours that continue to grow or worsen despite both medication and surgery, or for aggressive tumours that don’t respond to standard treatments^[8][9].

Two main types of radiation therapy can be used. Conventional radiation therapy delivers radiation to the tumour area over multiple treatment sessions, usually spread over several weeks. Stereotactic radiosurgery, despite its name, doesn’t involve actual surgery with incisions. Instead, it delivers highly focused beams of radiation to the tumour in one or just a few sessions. Gamma Knife is a well-known form of stereotactic radiosurgery. This precision targeting minimizes radiation exposure to surrounding healthy brain tissue^[8][16].

Radiation therapy works gradually. It may take months or even years for the full effects to become apparent, as the tumour slowly shrinks and hormone production decreases. During this time, patients often continue taking medication to control their prolactin levels. One important consideration with radiation therapy is the risk of developing hypopituitarism—a condition where the pituitary gland doesn’t produce enough of other essential hormones. This can happen years after radiation treatment, so patients require lifelong monitoring of their hormone levels and may need hormone replacement therapy^[15].

Most common treatment methods

• Dopamine agonist medication
  • Cabergoline (Dostinex) is the most commonly prescribed medication, taken once or twice weekly at doses typically ranging from 0.5 to 1 milligram, successfully normalizing prolactin levels in 80-90% of patients^[11][6].
  • Bromocriptine (Parlodel) requires dosing two to three times daily at 2.5 milligrams per dose and has been used effectively for many years^[11].
  • Quinagolide (Norprolac) is taken once daily with gradual dose increases to 75 micrograms, providing an alternative for patients who don’t respond to other medications^[11].
  • These medications work by mimicking dopamine, bringing prolactin levels down to normal within weeks and shrinking tumours in most cases^[9].
  • Treatment duration varies—some patients need lifelong therapy while others can stop after 2-3 years, especially if tumours were small or have disappeared^[8].
• Transsphenoidal surgery
  • Endoscopic transsphenoidal surgery is a minimally invasive approach that accesses the pituitary through the nose and sinuses without external incisions^[14][5].
  • Surgery is recommended when medications fail to control hormone levels, when patients cannot tolerate medications, or when severe symptoms like sudden vision loss require rapid intervention^[9][11].
  • Success rates are higher for smaller tumours and when surgery is performed by experienced pituitary surgeons at high-volume centers^[14].
  • Some patients may still require medication after surgery if the tumour cannot be completely removed^[11].
• Radiation therapy
  • Conventional radiation therapy delivers treatment over multiple sessions spanning several weeks^[8].
  • Stereotactic radiosurgery (including Gamma Knife) delivers highly focused radiation in one or few sessions, minimizing exposure to surrounding healthy tissue^[8][16].
  • Radiation is typically reserved for tumours that continue growing despite medication and surgery or for aggressive cases^[9].
  • Effects develop gradually over months to years, requiring continued monitoring and often ongoing medication during this period^[15].

Clinical Trials and Emerging Treatments

While standard treatments work well for most patients with prolactinomas, researchers continue seeking better options for the small percentage of people whose tumours resist conventional therapy. Clinical trials play a crucial role in advancing our understanding of prolactinomas and developing new treatment approaches. These studies test the safety and effectiveness of innovative therapies before they become widely available^[6][12].

Clinical trials for pituitary tumours, including prolactinomas, typically progress through three phases. Phase I trials focus primarily on safety—researchers carefully evaluate whether a new treatment causes harmful side effects and determine the appropriate dose. These studies usually involve small numbers of participants. Phase II trials expand to more patients and investigate whether the treatment actually works—does it lower prolactin levels, shrink tumours, or improve symptoms? Phase III trials are the largest and most rigorous, comparing the new treatment directly against current standard therapies to determine if it offers advantages^[15].

Research into prolactinomas explores several promising directions. Scientists are investigating why some tumours don’t respond well to dopamine agonists and whether genetic factors play a role. Understanding the molecular pathways that drive tumour growth could lead to targeted therapies that attack specific weaknesses in prolactinoma cells. Studies have identified genes like the pituitary tumour transforming gene (PTTG) and mutations in receptors for fibroblast growth factor 4 (FGF4) that appear in some prolactinomas, potentially offering future therapeutic targets^[3][13].

For patients with aggressive or resistant prolactinomas, researchers are exploring whether treatments used for other types of tumours might help. This includes investigating temozolomide, a chemotherapy drug that has shown promise in some aggressive pituitary tumours that don’t respond to standard treatments. While prolactinomas rarely require such aggressive therapy, having additional options available for the most challenging cases is important^[6].

Another area of investigation involves optimizing how existing dopamine agonists are used. Researchers study questions like: What is the best way to taper medication for patients who want to try stopping treatment? Can we predict which patients are most likely to successfully discontinue therapy without recurrence? How should we monitor patients who stop medication to catch any regrowth early? These clinical studies help refine treatment guidelines and improve outcomes^[6][12].

Clinical trials for prolactinomas take place at specialized medical centers around the world, including sites in Europe, the United States, and other countries. Eligibility for trials depends on many factors, including the size and behavior of the tumour, previous treatments, and how well current therapy is working. Patients interested in participating in clinical trials should discuss this option with their endocrinologist or neurosurgeon, who can help determine if any appropriate studies are available^[15].

Special Considerations for Pregnancy and Fertility

For many people with prolactinomas, concerns about fertility and pregnancy are paramount. The good news is that with proper treatment, most women and men with prolactinomas can successfully have children. However, managing prolactinomas during pregnancy requires careful planning and monitoring^[11][6].

Dopamine agonist treatment typically restores fertility quite rapidly in women with prolactinomas. This means that women who don’t wish to become pregnant should discuss effective contraception with their doctor before starting medication. For those who do want to conceive, preconception counseling with an endocrinologist is strongly recommended. This allows doctors to optimize treatment and discuss the plan for managing the prolactinoma during pregnancy^[11].

Once pregnancy is confirmed, most doctors recommend stopping dopamine agonist medication, particularly for women with microprolactinomas. Decades of data show that babies conceived while mothers were taking these medications have good safety outcomes. For women with larger macroprolactinomas, the decision about continuing medication during pregnancy is more complex. Large tumours can grow during pregnancy when they’re not being treated with medication, potentially causing headaches or vision problems. Each case requires individual assessment^[11][6].

Measuring prolactin levels during pregnancy isn’t helpful because prolactin naturally rises substantially in normal pregnancy—this is how the body prepares for breastfeeding. Instead, doctors monitor pregnant women with prolactinomas through regular check-ups, asking about symptoms like headaches or vision changes. If concerning symptoms develop, brain imaging can be performed safely during pregnancy^[11].

After delivery, women need reassessment by their endocrinologist to determine whether restarting medication is necessary. Those who wish to breastfeed should discuss this decision with their doctor. Breastfeeding itself doesn’t typically cause problems with prolactinomas, though the decision must balance the benefits of breastfeeding against any need to restart medication that might pass into breast milk^[11].

Living Well with a Prolactinoma

A diagnosis of prolactinoma understandably raises many concerns, but most people with this condition can expect to live normal, healthy lives with appropriate treatment. Regular follow-up care is essential to monitor how well treatment is working and catch any changes early. This typically involves periodic blood tests to measure prolactin and other hormone levels, along with brain imaging scans to assess tumour size^[2].

For those with large prolactinomas, especially when they have shrunk significantly with treatment, follow-up imaging helps ensure the tumour remains controlled. If the pituitary gland has been damaged—either by the tumour itself or by treatment—replacement of other hormones like thyroid hormone, cortisol, or sex hormones may be necessary. This condition, called hypopituitarism, requires lifelong hormone replacement and monitoring^[2][15].

Untreated high prolactin levels can lead to bone loss, increasing the risk of osteoporosis and fractures. This is one reason why maintaining prolactin levels in the normal range through treatment is so important. Women and men with prolactinomas should discuss bone health with their doctors, including whether bone density testing is appropriate and what steps can protect bone strength^[2][10].

Emotional and psychological support matters too. Living with a pituitary tumour can be stressful, and symptoms like fatigue, mood changes, and sexual difficulties can affect quality of life and relationships. Many medical centers offer support resources, including patient support groups where people with prolactinomas can connect with others facing similar challenges. Psychological counseling can help individuals and couples cope with the emotional impact of diagnosis and treatment^[18].

Maintaining overall health through good nutrition, regular exercise, adequate sleep, and stress management supports wellbeing for everyone, including those with prolactinomas. While no dietary supplements or alternative therapies have been proven to shrink prolactinomas, healthy lifestyle habits contribute to general health and may help people feel their best while managing their condition^[25].

Many patients wonder about long-term outlook. The prognosis for prolactinomas is generally excellent. These are benign tumours—they are not cancer and almost never spread to other parts of the body. The vast majority respond well to medication, with prolactin levels normalizing and tumours shrinking in most cases. Even when surgery or radiation is needed, outcomes are usually very good. With proper treatment and follow-up, most people with prolactinomas can work, exercise, have families, and enjoy life without significant limitations^[2][10].